Anonymous
Guest
Anonymous
Guest
FDA gave a month deadline for Mallinckrodt and UCB to prove that their generic is equivalent to the innovator product. Mallinckrodt ignored the deadline and refused to provide any information to the FDA . UCB officials say they have been working to meet FDA requirements. Any generic that fails to prove equivalence will be pulled from the market by the FDA. Mallinckrodt CEO Mark Trudeau said the company has no plans to remove its drug from pharmacy shelves.
Instead, Mallinckrodt filed a lawsuit challenging the FDA ruling that the drugs were not equivalent, saying that the agency encouraged patients to continue taking the generic ADHD medications if they weren't experiencing any issues.
Regulate this FDA - all together, bend each finger beside your middle finger, extend the middle finger and raise your hand... F*ck You FDA
Instead, Mallinckrodt filed a lawsuit challenging the FDA ruling that the drugs were not equivalent, saying that the agency encouraged patients to continue taking the generic ADHD medications if they weren't experiencing any issues.
Regulate this FDA - all together, bend each finger beside your middle finger, extend the middle finger and raise your hand... F*ck You FDA